Aptamer Group unveils rapid biomarker discovery platform
A new service from Aptamer Group promises to reduce biomarker discovery timelines from years to months, reshaping how pharmaceutical and diagnostic companies approach disease marker identification. The platform combines cutting-edge synthetic biology with advanced proteomics to deliver both validated biomarkers and functional binding tools simultaneously.
Synthetic binders accelerate traditional discovery bottlenecks
The service integrates Aptamer’s proprietary Optimer technology with advanced proteomic analysis, creating an unbiased, high-throughput discovery engine. Unlike traditional approaches that require separate identification and validation phases, this methodology simultaneously identifies biomarkers and generates corresponding affinity ligands as aptamers.
Optimers – short, synthetic oligonucleotide molecules engineered for enhanced stability and binding specificity – serve as molecular scouts, distinguishing healthy from diseased cell and tissue samples. Subsequent proteomic analysis pinpoints precise molecular biomarkers, delivering validated targets alongside immediately functional aptamers.
Strategic biomarker identification enhances therapeutic translation
The platform addresses multiple critical research objectives: target identification for novel therapeutic interventions, biomarker validation for precision medicine applications, diagnostic marker discovery for early disease detection, and companion diagnostic development for therapeutic monitoring. Crucially, the service can identify biomarkers that support specific drug development strategies, such as receptor-mediated endocytosis for enhanced drug delivery approaches.
This approach significantly improves biomarker translation potential whilst further compressing development timelines.
Clinical validation demonstrates platform effectiveness
Aptamer Group validated this approach through internal identification of biomarkers for fibrotic liver targeting, demonstrating the platform’s capability to deliver actionable research outputs with immediate therapeutic and diagnostic relevance.
“Our biomarker discovery service addresses a fundamental challenge in life sciences research, which is the need for faster, more efficient identification of clinically relevant molecular targets,” commented Dr Arron Tolley, Chief Executive Officer of Aptamer Group. “By combining our Optimer libraries with proteomic capabilities, we can deliver validated biomarkers alongside functional binding tools, significantly accelerating the translation from discovery to application.”
Available through a fee-for-service framework, the platform eliminates infrastructure investment barriers whilst providing access to sophisticated discovery capabilities. Aptamer operates within the US$210 billion antibody
alternatives market, collaborating with all top 10 global pharmaceutical companies.
For more information, visit:
https://aptamergroup.com/biomarker-discovery-service
Digital issue: Please click here for more information
